CRDF vs KPTI

For growth investors, Karyopharm Therapeutics Inc.

(KPTI) is the stronger pick with 0. 6% revenue growth year-over-year, versus -13. 2% for Cardiff Oncology, Inc. (CRDF). Analysts rate Cardiff Oncology, Inc. (CRDF) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Cardiff Oncology, Inc.

(CRDF) delivered a total return of -79. 8%, compared to -94. 2% for Karyopharm Therapeutics Inc. (KPTI). Over 10 years, the gap is even starker: KPTI returned -92. 8% versus CRDF's -99. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Karyopharm Therapeutics Inc.

(KPTI) is the lower-risk stock at 1. 50β versus Cardiff Oncology, Inc. 's 2. 23β — meaning CRDF is approximately 48% more volatile than KPTI relative to the S&P 500.

By revenue growth (latest reported year), Karyopharm Therapeutics Inc.

(KPTI) is pulling ahead at 0. 6% versus -13. 2% for Cardiff Oncology, Inc. (CRDF). On earnings-per-share growth, the picture is similar: Cardiff Oncology, Inc. grew EPS 27. 4% year-over-year, compared to -90. 5% for Karyopharm Therapeutics Inc.. Over a 3-year CAGR, CRDF leads at 15. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Karyopharm Therapeutics Inc.

(KPTI) is the more profitable company, earning -134. 2% net margin versus -77. 3% for Cardiff Oncology, Inc. — meaning it keeps -134. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KPTI leads at -62. 1% versus -82. 6% for CRDF. At the gross margin level — before operating expenses — CRDF leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Karyopharm Therapeutics Inc.

(KPTI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Cardiff Oncology, Inc. (CRDF) carries a higher beta of 2. 23 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KPTI: -92. 8%, CRDF: -99. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.